Roche's Tecentriq cocktail adds to lung cancer survival success

ZURICH (Reuters) – Roche’s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients’ survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *